Primary Objective: To evaluate the safety of CYD-TDV in pregnant women and their offsprings inadvertently exposed during pregnancy or up to 30 days preceding their last menstrual period (LMP) with regards to maternal, pregnancy, birth, neonatal and infant outcomes. Specifically, the frequency/rates of these outcomes will be: (i) described, and (ii) compared with population-level background incidence rates prior to the introduction of CYD-TDV immunization (i.e., external unvaccinated comparator). Secondary Objective: To describe: * the characteristics of women exposed to CYD-TDV during pregnancy or up to 30 days before the LMP * the characteristics of CYD-TDV pregnancy exposure with regards to number of doses, dose intervals, and trimester of exposure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of pregnant women with maternal adverse events
Timeframe: From cohort entry up to 42 days post-end of pregnancy
Percentage of pregnant women with pregnancy related adverse events
Timeframe: From cohort entry to up to 42 days post-end of pregnancy
Percentage of offsprings with adverse birth outcomes
Timeframe: On day of birth (DOB)
Percentage of offsprings with adverse neonatal events
Timeframe: From DOB up to 28 days post-birth
Percentage of offsprings with adverse infant events
Timeframe: From day 29 post-birth up to 12 months post-birth